MMP-9 microsatellite polymorphism and multiple sclerosis

Journal of Neuroimmunology

Volumn 152, Issue 1-2, 2004, Pages 147-153

  Fiotti, Nicola ^a,c   Zivadinov, Robert ^a,b   Altamura, Nicola ^a   Nasuelli, Davide ^a   Bratina, Alessio ^a   Tommasi, Maria Antonietta ^a   Bosco, Antonio ^a   Locatelli, Laura ^a   Grop, Attilio ^a   Cazzato, Giuseppe ^a   Guarnieri, Gianfranco ^a   Giansante, Carlo ^a   Zorzon, Marino ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

MMP 9; MRI; Multiple sclerosis

Indexed keywords

ADENINE; CYTOSINE; GELATINASE B; MICROSATELLITE DNA;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGE OF ONSET; BRAIN; FEMALE; GENETIC MARKERS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MICROSATELLITE REPEATS; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 3042610060     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2004.03.009     Document Type: Article

References (32)

1. Anthony D.C., Miller K.M., Fearn S., Townsend M.J., Opdenakker G., Wells G.M., Clements J.M., Chandler S., Gearing A.J., Perry V.H. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J. Neuroimmunol. 87:1998;62-72
2. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., Livrea P., Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 136:2003;46-53
3. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Valk P., De Groot C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 6:1997;590-598
4. Cuzner M.L., Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94:1999;1-14
5. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104:1999;1507-1515
6. Fiten P., Vandenbroeck K., Dubois B., Van Coillie E., Nelissen I., Van Damme J., Ligers A., Hillert J., Andersson M., Olsson T., Opdenakker G. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J. Neuroimmunol. 95:1999;195-201
7. Fornoni A., Wang Y., Lenz O., Striker L.J., Striker G.E. Association of a decreased number of d(CA) repeats in the matrix metalloproteinase-9 promoter with glomerulosclerosis susceptibility in mice. J. Am. Soc. Nephrol. 13:2002;2068-2076
8. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842:1999;92-100
9. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann. Neurol. 50:2001;443-451
10. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J.M., Crimmin M., Davidson A.H., Drummond A.H., Galloway W.A., Gilbert R. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 370:1994;555-557
11. Grimaud J., Lai M., Thorpe J., Adeleine P., Wang L., Barker G.J., Plummer D.L., Tofts P.S., McDonald W.I., Miller D.H. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn. Reson. Imaging. 14:1996;495-505
12. Ito A., Mukaiyama A., Itoh Y., Nagase H., Thogersen I.B., Enghild J.J., Sasaguri Y., Mori Y. Degradation of interleukin 1beta by matrix metalloproteinases. J. Biol. Chem. 271:1996;14657-14660
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452
14. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain. 122:1999;191-197
15. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334
16. Lichtinghagen R., Seifert T., Kracke A., Marckmann S., Wurster U., Heidenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J. Neuroimmunol. 99:1999;19-26
17. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911
18. Miller D.H., Barkhof F., Berry I., Kappos L., Scotti G., Thompson A.J. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J. Neurol. Neurosurg. Psychiatry. 54:1991;683-688
19. Nelissen I., Vandenbroeck K., Fiten P., Hillert J., Olsson T., Marrosu M.G., Opdenakker G. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis. J. Neuroimmunol. 105:2000;58-63
20. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 10:2001;571-579
21. Poser C.M., Paty D.W, Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 12:1983;227-231
22. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist. 8:2002;586-595
23. Rosenberg G.A., Dencoff J.E., Correa N. Jr., Reiners M., Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 46:1996;1626-1632
24. Sellebjerg F., Madsen H.O., Jensen C.V., Jensen J., Garred P. CCR5 delta 32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102:2000;98-106
25. Shimajiri S., Arima N., Tanimoto A., Murata Y., Hamada T., Wang K.Y., Sasaguri Y. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 455:1999;70-74
26. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong V.W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863
27. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., Santacroce M.P., Paolicelli D., Giuliani F., Riccio P., Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNB-1b treatment in relapsing-remitting MS. Neurology. 53:1999;1402-1408
28. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., Andersson P.B., Stabler G., Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 53:1999;1397-1401
29. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19:2000;623-629
30. Yoon S., Tromp G., Vongpunsawad S., Ronkainen A., Juvonen T., Kuivaniemi H. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem. Biophys. Res. Commun. 265:1999;563-568
31. Zivadinov R., De Masi R., Nasuelli D., Bragadin L.M., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. MRI techniques and cognitive impairment in early phase of relapsing-remitting multiple sclerosis. Neuroradiology. 43:2001;272-278
32. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis. Neurology. 57:2001;1239-1247